Streetbeat News

Products Services

PLTR

Palantir Technologies Inc. (NYSE:PLTR) shares surged in premarket trading after securing a $178.4 million contract from the Army Contracting Command for the TITAN ground station system, leveraging AI and ML for deep-sensing capabilities. Additionally, Palantir announced over 60 customers will showcase at its AIPCon, including 20+ new customers and partners. The company also revealed a new partnership with the Ministry of Economy of Ukraine, contributing to the stock's 9.45% increase to $26.06.

Portfolio Pulse from Nabaparna Bhattacharya

March 06, 2024 | 1:53 pm

HSAI

LI

Hesai has been chosen as the LiDAR supplier for Li Auto's new model, Li MEGA, marking a significant partnership in the automotive and technology sectors.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:48 pm

CETX

Cemtrex Inc. (NASDAQ:CETX) announced its subsidiary, Vicon, will begin the beta release of an AI gun detection feature in Q2 2024, aiming for full commercialization in the second half of 2024. This edge-based solution is designed to enhance public safety by detecting armed individuals in surveillance footage, offering a cost-effective alternative to server-based systems. The technology, developed in collaboration with partners, aims to provide real-time alerts and rapid response to potential threats, addressing the urgent need for innovative solutions to gun violence in the U.S.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:48 pm

CVM

CEL-SCI Corporation (NYSE:CVM) issued a shareholder letter detailing progress on Multikine, a pre-surgical cancer therapy for head and neck cancer. The therapy showed significant survival benefits in a specific patient population, leading to regulatory filings for marketing clearance. CEL-SCI completed its manufacturing facility commissioning and is in discussions with major regulatory bodies including the FDA, EMA, MHRA, and Health Canada. The company plans to seek immediate patient access to Multikine through conditional approvals.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:47 pm

OMQS

OMNIQ Corp. has received a purchase order from Burger Ranch for the supply of self-ordering kiosks, self-check-out kiosks, and a new feature supporting cash transactions. This development signifies an expansion of OMNIQ's market presence in the fast-food industry and highlights the growing trend of automation in retail and hospitality sectors.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:46 pm

DTIL

Precision BioSciences has announced that its partner, iECURE, received MHRA approval to expand the Phase 1/2 clinical trial of the ARCUS gene editing program for treating OTC deficiency. This development marks a significant step forward in the application of gene editing technologies in addressing genetic disorders.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:45 pm

NVNO

EnVVENO Medical announced positive topline efficacy data from its VenoValve pivotal trial, to be presented at VENOUS2024. The data shows 97% of patients experienced clinical improvement, with 74% showing meaningful benefit. The average improvement was 8 points on the rVCSS, significantly above the threshold for clinical relevance. The company plans to seek FDA approval for VenoValve in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:42 pm

HBIO

Harvard Bioscience, Inc. (NASDAQ:HBIO) announced its participation in the Society of Toxicology conference in Salt Lake City from March 11-13, 2024, showcasing its latest product innovations for preclinical and organoid applications. The company introduced the Ponemah Data Management Platform, SoHo Implantable Telemetry, VivaMARS Activity Monitoring System, and Mesh MEA Organoid Platform, highlighting their integration and potential for advancing therapy development with AI and machine learning technologies.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:40 pm

CISO

CISO Global (NASDAQCM: CISO) announced a 1-for-15 reverse stock split effective March 7, 2024, to reduce outstanding shares from 180 million to 12 million, aiming to increase share price for Nasdaq compliance and future value creation. The adjustment includes equity-based awards, warrants, and convertible notes, with no fractional shares issued. The stock will trade under a new CUISP and ISIN number starting March 8, 2024. Additionally, CISO is deploying an AI-powered security solutions suite valued over $50 million.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:39 pm

PINC

Premier, Inc. has announced a clinical research collaboration with McLaren Health Care through its PINC AI Applied Sciences division. The partnership aims to advance patient outcomes by leveraging Premier's healthcare performance improvement capabilities and McLaren's healthcare delivery expertise.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:39 pm